PBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Prestige Consumer Healthcare Inc (PBH) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The company's recent financial performance shows declining revenue, net income, and EPS, while analyst sentiment is mixed with lowered price targets and no significant positive catalysts. The technical indicators suggest a neutral trend, and there are no strong proprietary trading signals or recent news to drive immediate upside. Given the lack of compelling reasons to invest now, holding off for a better entry point or clearer catalysts is recommended.
The MACD is positive and expanding, indicating slight bullish momentum. RSI is neutral at 62.526, and moving averages are converging, suggesting no clear trend. Key resistance is at $67.924, and support is at $63.898. Overall, the technical indicators are neutral.
Hedge funds are significantly increasing their buying activity, up 622.44% over the last quarter.
Declining financial performance in Q3 2026, with revenue down 2.37%, net income down 23.49%, and EPS down 20.49%. Analysts have lowered price targets, and there are no recent news or event-driven catalysts. Insider trading is neutral, and there is no recent congress trading data.
In Q3 2026, revenue dropped to $283.4M (-2.37% YoY), net income dropped to $46.7M (-23.49% YoY), and EPS dropped to $0.97 (-20.49% YoY). Gross margin slightly decreased to 53.7% (-0.13% YoY).
Analysts are mixed. Canaccord maintains a Buy rating but lowered the price target to $86 from $88. Jefferies maintains a Hold rating and lowered the price target to $66 from $70, citing range-bound shares and lack of catalysts. Other analysts have not provided significant updates recently.
